Vibostolimab

• Description:

  Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research[1].

• UNSPSC:

  12352203

• Target:

  Transmembrane Glycoprotein

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vibostolimab.html

• Purity:

  96.54

• Solubility:

  10 mM in DMSO

• Smiles:

  [Vibostolimab]

• Molecular Weight:

  (144.5 kDa)

• References & Citations:

  [1]Niu J, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2022 Feb;33 (2) :169-180.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2

• CAS Number:

  [2231305-30-7]